🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

18 recruiting trials

for Ras-mutated Metastatic Colorectal Cancer

Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC NCT07224841n/a1 site📍 Duarte City of Hope Medical Center · Tests: cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation) FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients NCT05727163Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Dexamethasone, Anisodamine, Oxaliplatin, Leucovorin, Fluorouracil FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer NCT07446322Phase 219 sites📍 Homewood📍 Beverly Hills📍 Encino Oncolytics Biotech · Tests: Bevacizumab, FOLFIRI, Pelareorep Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer NCT06218810Phase 21 site📍 Shanghai Fudan University · Tests: Cadonilimab + bevacizumab + FOLFOX Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924Phase 1, Phase 249 sites📍 Gilbert📍 Los Angeles📍 Los Angeles Institut de Recherches Internationales Servier · Tests: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338Phase 1, Phase 29 sites📍 Los Angeles📍 Norwich📍 Saint Paul Revolution Medicines, Inc. · Tests: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer NCT07213570Phase 21 site📍 Naples National Cancer Institute, Naples · Tests: standard second line treatment, at discretion of the investigator, Regorafenib (BAY73-4506) A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites📍 Los Angeles📍 Sarasota📍 Tampa Kestrel Therapeutics, Inc. · Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6 Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer NCT06763029Phase 21 site📍 Shanghai Fudan University · Tests: Irinotecan liposomes combined with cetuximab + vermofenib Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors NCT06128551Phase 1, Phase 256 sites📍 Duarte📍 Orange📍 Sacramento Revolution Medicines, Inc. · Tests: Elironrasib, Daraxonrasib Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer NCT06566755Phase 31 site📍 Shenyang Caigang Liu · Tests: Cadonilimab (AK104) combined with chemotherapy and bevacizumab A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221Phase 1, Phase 220 sites📍 Los Angeles📍 Baltimore📍 Boston Verastem, Inc. · Tests: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes NCT06949982Phase 21 site📍 Saint Petersburg Sergey Orlov, MD · Tests: experimental group x-MAP, Regorafenib (BAY 73-4506) cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer NCT07224815n/a1 site📍 Duarte City of Hope Medical Center · Tests: cfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase), EpiCORE Assay (Targeted Sequencing / qPCR Validation) ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC NCT06321081Phase 21 site📍 Beijing Beijing Hospital · Tests: irinotecan, cetuximab, envafolimab Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer NCT06449989n/a1 site📍 Moscow Blokhin's Russian Cancer Research Center · Tests: Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer NCT04678583NA37 sites📍 Mannheim📍 Dresden📍 Ansbach Technische Universität Dresden · Tests: Resection of colorectal liver metastases Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062Phase 1, Phase 232 sites📍 Chandler📍 Phoenix📍 Scottsdale Revolution Medicines, Inc. · Tests: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy